Survodutide
Dual GLP-1/glucagon receptor agonist. Phase 3 SYNCHRONIZE-1: 16.6% weight loss.
Mechanism of Action
Bioregulator compound with targeted biochemical activity.
Evidence Chain
Survodutide
COMPOUND
1 Research Goal
• Weight Management
Evidence Strength
3 articles sourced
Knowledge Graph
(4 connections)Research Evidence
(3)Survodutide (BI 456906): Dual GLP-1/Glucagon Receptor Agonist — Clinical Evidence in Obesity and MASH
Survodutide is a dual GLP-1 and glucagon receptor agonist in clinical development by Boehringer Ingelheim for obesity and metabolic dysfunction-associated steatohepatitis (MASH). This review summarizes the clinical evidence.
CagriSema (Cagrilintide + Semaglutide) Combination Therapy: Clinical Evidence from the REDEFINE Trial Program
CagriSema combines cagrilintide (a long-acting amylin analogue) with semaglutide (a GLP-1 receptor agonist) for the treatment of obesity. The REDEFINE clinical development program evaluates the additive weight-loss effects of co-administering amylin and incretin pathway agonism.
Peptide Synergy: Metabolic System Stacking
A systematic review of metabolic peptide synergy, examining how dual and triple receptor agonists interact within the incretin pathway.
Overview
Survodutide (BI 456906) is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. As a dual agonist targeting both incretin and glucagon pathways, Survodutide represents an important class of metabolic peptides that aim to achieve weight loss and metabolic improvements through complementary mechanisms. It is currently in Phase 3 clinical trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH).
Mechanism of Action
Survodutide simultaneously activates GLP-1 and glucagon receptors, producing complementary metabolic effects. GLP-1 receptor activation suppresses appetite, improves glycemic control, and slows gastric emptying. Glucagon receptor activation promotes hepatic fatty acid oxidation, increases energy expenditure, and may contribute to greater fat mass reduction. The dual mechanism is designed to achieve weight loss results that may exceed those of selective GLP-1 agonists, while the glucagon component may provide additional benefits for liver fat reduction.
Research Highlights
The Phase 2 trial demonstrated mean weight loss of up to 16.6% at 46 weeks, establishing Survodutide as a promising dual agonist. Research showed significant improvements in liver fat content and markers of MASH, leading to Phase 3 trials specifically targeting this indication. The SYNCHRONIZE Phase 3 program is investigating Survodutide for obesity and MASH, with results anticipated to provide further efficacy and safety data. Studies have shown that the glucagon receptor component may provide advantages in liver disease compared to GLP-1-only agonists.
Dosage & Administration
In clinical trials, Survodutide is administered via subcutaneous injection once weekly, with dose escalation to minimize gastrointestinal side effects. For research use only (RUO) — not yet FDA-approved.
Safety Profile
Reported side effects are consistent with the incretin/glucagon agonist class, including nausea, vomiting, diarrhea, and constipation. The glucagon receptor component may contribute to additional effects on hepatic glucose output. Long-term safety data is being collected in ongoing Phase 3 trials. Not yet approved by the FDA for any indication.
References
Whaley JM, et al. Survodutide Phase 2 results. Presented at medical conferences. Boehringer Ingelheim clinical trial data (NCT04667377). All content is for educational and research purposes only.
Related Compounds
Synergy & Compatibility
(5)Computational assessment of bio-regulatory compatibility with compounds sharing research goals. Scores reflect half-life alignment, receptor target overlap, and bioavailability data.
Highest Compatibility
Survodutide + CagriSema
High Compatibility
Shared targets: glp-1 receptor
Computational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.
Community Observations
(0)Qualitative, self-reported researcher observations. Distinct from peer-reviewed evidence — not medical advice.
No approved observations yet. Sign in to contribute.
For research use only. Not medical advice.